CORC

在结果中检索

CORC

浏览/检索结果: 共101条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang
收藏  |  浏览/下载：92/0  |  提交时间：2022/03/28
YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer 期刊论文
BRITISH JOURNAL OF CANCER, 2020, 页码: 12
作者:  Wang, Lei;  Wang, Quanren;  Xu, Piaopiao;  Fu, Li;  Li, Yun
收藏  |  浏览/下载：15/0  |  提交时间：2020/12/24
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial 期刊论文
CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:  Li, Qiao;  Guan, Xiuwen;  Chen, Shanshan;  Yi, Zongbi;  Lan, Bo
收藏  |  浏览/下载：15/0  |  提交时间：2020/07/01
LncRNAs GIHCG and SPINT1-AS1 Are Crucial Factors for Pan-Cancer Cells Sensitivity to Lapatinib. 期刊论文
Frontiers in genetics, 2019, 卷号: Vol.10, 页码: 25
作者:  Zhen Xiang;  Shuzheng Song;  Zhenggang Zhu;  Wenhong Sun;  Jaron E Gifts
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/13
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study 期刊论文
2019, 卷号: 37, 期号: 29, 页码: 2610-2619
作者:  Ma Fei;  Ouyang Quchang;  Li Wei;  Jiang Zefei;  Tong Zhongsheng
收藏  |  浏览/下载：32/0  |  提交时间：2020/01/03
Fructus mume Extracts Alleviate Diarrhea in Breast Cancer Patients Receiving the Combination Therapy of Lapatinib and Capecitabine 期刊论文
FRONTIERS IN PHARMACOLOGY, 2018, 卷号: 9
作者:  Song, Changlong;  Liu, Yuxia;  Liu, Zhen;  Ma, Jinshu;  Xing, Hua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab 期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:  Xu, Binghe;  Ma, Fei;  Ouyang, Quchang;  Li, Wei;  Jiang, Zefei
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05
A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab 会议论文
作者:  Xu, Binghe;  Ma, Fei;  Ouyang, Quchang;  Li, Wei;  Jiang, Zefei
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report 期刊论文
BMC CANCER, 2018, 卷号: 18
作者:  Jiao, Xiao-Dong;  Ding, Chunming;  Zang, Yuan-Sheng;  Yu, Guanzhen
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
miR-494 inhibits cancer-initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2-positive gastric cancer 期刊论文
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 卷号: 42, 期号: 2, 页码: 998-1007
作者:  Yu, Yanxia;  Yu, Xuejuan;  Liu, Hong;  Song, Qingxun;  Yang, Yongmei
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/11

©版权所有 ©2017 CSpace - Powered by CSpace